From Neuropathy to Cardiomyopathy: How to Never Miss Amyloidosis
From Neuropathy to Cardiomyopathy: How to Never Miss Amyloidosis is organized by Emory University School of Medicine Office of Continuing Medical Education (OCME) and will be held on May 11, 2019 at Emory Conference Center Hotel, Atlanta, Georgia, United States of America.
This symposium is appropriate for primary care providers, neurologist, cardiologists and hematology/oncology.
Continuing Education Credit:
The Emory University School of Medicine designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCE for the purpose of granting ABIM MOC credit.
The Emory University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
It has been estimated that approximately 12,000 patients will develop systemic amyloidosis each year in the U.S., but unfortunately many of them will suffer for years prior to definitive diagnosis. There are now comprehensive genetic tests and pyrophosphate cardiac imaging to make the diagnosis earlier and more accurately. Three new drugs for TTR Amyloid that improve cardiac and peripheral nerve were all FDA approved in 2018.
The learner will leave with modern diagnostic algorithms to work-up progressive sensorimotor neuropathy, kidney dysfunction with proteinuria, and restrictive cardiomyopathy. Learners will hear from experts about the new TTR treatments focusing on who will benefit, costs, side effects, and the logistics of these chronic therapies.
At this symposium, learners will hear from experts about the new TTR treatments focusing on who will benefit, costs, side effects, and the logistics of these chronic therapies.
Upon completion of this education activity, learners should be able to:
• Identify hereditary ATTR symptoms and best treatments;
• Recognize a modern diagnostic algorithm for proteinuria and chronic kidney disease highlighting patients in need of a kidney biopsy;
• Utilize diagnostic algorithm for restrictive cardiomyopathy;
• Discuss AL Amyloidosis and diagnostic algorithms along with modern treatments.
Additional details will be posted as soon as they are available.
|Contact No. :|| 404-727-3612
|Registration Type||End Date||Price|
|Physician Fee||11 May,2019||USD 75.00|
|Allied Healthcare Professionals Fee||11 May,2019||USD 50.00|